1. Di Lorenzo G, Pacor ML, Amodio E, Leto-Barone MS, La Piana S, D’Alcamo A, et al. Differences and similarities between allergic and nonallergic rhinitis in a large sample of adult patients with rhinitis symptoms. International archives of allergy and immunology. 2011;155(3):263-70 2. Zhang L, Han D, Huang D, Wu Y, Dong Z, Xu G, et al. Prevalence of self-reported allergic rhinitis in eleven major cities in china. International archives of allergy and immunology. 2009;149(1):47-57. 3. Mahboubi Oskouei Y, Farid Hosseini R, Ahanchian H, Jarahi L, Ariaee N, Jabbari Azad F. Report of Common Aeroallergens among Allergic Patients in Northeastern Iran. Iranian journal of Otorhinolaryngology. 2017;29(91):89. 4. Dursun A, Sin B, Oner F, Misirligil Z. The safety of allergen immunotherapy (IT) in Turkey. Journal of investigational allergology and clinical immunology. 2006;16(2):123. 5. Brüggenjürgen B, Reinhold T, Brehler R, Laake E, Wiese G, Machate U, et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Annals of Allergy, Asthma&Immunology. 2008;101(3): 316-24. 6. Walker S, Varney V, Gaga M, Jacobson M, Durham S. Grass pollen immunotherapy: efficacy and safety during a 4‐year follow‐up study. Allergy. 1995;50(5):405-13. 7. Cox L, Calderon MA. Subcutaneous specific immunotherapy for seasonal allergic rhinitis: a review of treatment practicesin the US and Europe. Current medical research and opinion. 2010;26(12):2723-33. 8. Wambre E, DeLong JH, James EA, LaFond RE, Robinson D, Kwok WW. Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. Journal of Allergy and Clinical Immunology. 2012;129(2):544-51. e7. 9. Moote W, Kim H. Allergen-specific immunotherapy. Allergy, Asthma & Clinical Immunology. 2011;7(1):S5. 10. Sheikh A, Hurwitz B, Shehata Y. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev. 2007;1. 11. SchwankeT, Carragee E, Bremberg M, Reisacher WR. Quality-of-life outcomes in patients who underwent subcutaneous immunotherapy and sublingual immunotherapy in a real-world clinical setting. American journal of rhinology & allergy. 2017;31(5):310-6. 12. Roger A, Campillo EA, Torres M, Millan C, Jáuregui I, Mohedano E, et al. Reduced work/academic performance and quality of life in patients with allergic rhinitis and impact of allergen immunotherapy. Allergy, Asthma & Clinical Immunology. 2016;12(1):40. 13. Corsico AG, De Amici M, Ronzoni V, Giunta V, Mennitti MC, Viscardi A, et al. Allergen-specific immunoglobulin E and allergic rhinitis severity. Allergy & Rhinology. 2017;8(1):e1. 14. Lee J-H, Kim S-H, Lee WY, Yong SJ, Shin KC, Lee MK, et al. Immunotherapy -2079. Comparisonof house dust mite specific IgE and IgG4 between patients receiving rush immunotheraopy and conventional immunotherapy. World Allergy Organization Journal. 2013;6(1):P161-P.